0001415889-18-001434.txt : 20180926 0001415889-18-001434.hdr.sgml : 20180926 20180926193735 ACCESSION NUMBER: 0001415889-18-001434 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180926 FILED AS OF DATE: 20180926 DATE AS OF CHANGE: 20180926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38662 FILM NUMBER: 181089183 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUTRO BIOPHARMA INC CENTRAL INDEX KEY: 0001382101 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452441988 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 310 UTAH AVE., SUITE 150 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-392-8412 MAIL ADDRESS: STREET 1: 310 UTAH AVE., SUITE 150 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 form3-09262018_040920.xml X0206 3 2018-09-26 0 0001382101 SUTRO BIOPHARMA INC STRO 0000816284 CELGENE CORP /DE/ 86 MORRIS AVENUE SUMMIT NJ 07901 false false true false Series C-2 Redeemable Convertible Preferred Stock Common Stock 337725 D Series D Redeemable Convertible Preferred Stock Common Stock 115227 D Series D-2 Redeemable Convertible Preferred Stock Common Stock 758278 D Series E Redeemable Convertible Preferred Stock Common Stock 514967 D Each share of Series C-2 redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Each share of Series D redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Each share of Series D-2 redeemable convertible preferred stock is convertible into 0.0419 share of common stock without payment of further consideration and will automatically convert into 0.0419 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Each share of Series E redeemable convertible preferred stock is convertible into 0.0275 share of common stock without payment of further consideration and will automatically convert into 0.0275 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. /s/ David Elkins, EVP and Chief Financial Officer 2018-09-26